Physician profile
Chad Gerrish
NPI 1063738458
$892.33
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $69.36 · 2021: $14.14 · 2022: $251 · 2023: $98.84 · 2024: $78.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $162 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $162.16 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $283.65 | 2019-2024 | |
| Lilly USA, LLC | $114.57 | 2019 | |
| Glaxosmithkline, LLC. | $104.65 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $78.48 | 2022-2023 | |
| Novo Nordisk INC | $54.80 | 2022-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $52.10 | 2019 | |
| Abbvie INC. | $46.74 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $39.03 | 2022 | |
| Allergan, INC. | $20.09 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.03 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.45 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.59 | 2024 | Jardiance |
| Alkermes, INC. | $14.85 | 2023 | Vivitrol |
| Merck Sharp & Dohme LLC | $14.32 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Gerrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.